There are no significant differences in outcomes post-AMI in patients with systemic lupus erythematosus vs the general population.

The Global Systemic Lupus Erythematosus Treatment Market is valued approximately at USD 2.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.64% over the forecast ...

Current treatment options for systemic lupus erythematosus (SLE) consists of glucocorticoids, antimalarials, immunosuppressives, and a few biologics, approved or of 'off-label'. Through judicious ...

Immune cells called monocytes produce a key inflammatory protein called interleukin-1 beta (IL-1β) through an unconventional ...

SLE: Systemic lupus erythematosus. Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and afford the patient a better quality of life.

Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

Systemic lupus can be mild or severe. Cutaneous lupus erythematosus This form of lupus is limited to the skin and can cause many types of rashes and lesions. Drug-induced lupus erythematosus This is a ...

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

Exocrine pancreatic insufficiency (EPI) occurs in chronic pancreatitis, cystic fibrosis, autoimmune disorders such as Crohn’s disease and systemic lupus erythematosus and patients that have had parts ...

Preconception predictors of adverse pregnancy outcomes among women with SLE include previous lupus nephritis, chronic hypertension, SLE disease activity, and APS.